K
Kristin Stadelman
Researcher at Wake Forest University
Publications - 16
Citations - 909
Kristin Stadelman is an academic researcher from Wake Forest University. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Protein kinase B. The author has an hindex of 11, co-authored 16 publications receiving 830 citations. Previous affiliations of Kristin Stadelman include East Carolina University & Wake Forest Baptist Medical Center.
Papers
More filters
Journal ArticleDOI
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
Nicole Marie Davis,Melissa L. Sokolosky,Kristin Stadelman,Stephen L. Abrams,Massimo Libra,Saverio Candido,Ferdinando Nicoletti,Jerry Polesel,Roberta Maestro,Antonino B. D'Assoro,Lyudmyla Drobot,Dariusz Rakus,Agnieszka Gizak,Piotr Laidler,Joanna Dulińska-Litewka,Jörg Bäsecke,Sanja Mijatović,Danijela Maksimović-Ivanić,Giuseppe Montalto,Melchiorre Cervello,Timothy L. Fitzgerald,Zoya N. Demidenko,Alberto M. Martelli,Lucio Cocco,Linda S. Steelman,James A. McCubrey +25 more
TL;DR: The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will be reviewed in association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway.
Journal ArticleDOI
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
Linda S. Steelman,Patrick M. Navolanic,Melissa L. Sokolosky,Jackson R. Taylor,Brian D. Lehmann,William H. Chappell,Steven L. Abrams,Ellis W.T. Wong,Kristin Stadelman,David M. Terrian,Nick R. Leslie,C. Alberto M. Martelli,Franca Stivala,Massimo Libra,Richard A. Franklin,James A. McCubrey +15 more
TL;DR: It is indicated that disruption of the normal activity of the PTEN phosphatase can have dramatic effects on the therapeutic sensitivity of breast cancer cells and alter the sensitivity of cancer patients to chemo- and targeted therapies.
Journal ArticleDOI
Akt as a therapeutic target in cancer.
Linda S. Steelman,Kristin Stadelman,William H. Chappell,Stefan Horn,Jörg Bäsecke,Melchiorre Cervello,Ferdinando Nicoletti,Massimo Libra,Franca Stivala,Alberto M. Martelli,James A. McCubrey +10 more
TL;DR: The PI3K/PTEN/Akt/mTOR pathway is frequently aberrantly regulated in various cancers and targeting this pathway with small molecule inhibitors and may result in novel, more effective anticancer therapies.
Journal ArticleDOI
Yin Yang 1 contains G-quadruplex structures in its promoter and 5′-UTR and its expression is modulated by G4 resolvase 1
Weiwei Huang,Philip J. Smaldino,Qiang Zhang,Lance D. Miller,Paul Cao,Kristin Stadelman,Meimei Wan,Banabihari Giri,Ming Lei,Yoshikuni Nagamine,James P. Vaughn,Steven A. Akman,Guangchao Sui +12 more
TL;DR: Strong evidence is provided showing the presence of G4 structures in the promoter and the 5′-UTR of YY1, and the analysis of a gene array data consisting of the breast cancer samples of 258 patients indicates a significant, positive correlation between G4R1 and YY 1 expression.
Journal ArticleDOI
A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies
Timothy S. Pardee,King Chung Lee,John Luddy,Claudia Maturo,Robert J. Rodriguez,Scott Isom,Lance D. Miller,Kristin Stadelman,Denise Levitan,David D. Hurd,Leslie R. Ellis,Robin Harrelson,Megan Manuel,Sarah Dralle,Susan Lyerly,Bayard L. Powell +15 more
TL;DR: CP-613 inhibits mitochondrial function and demonstrates activity in a heavily pretreated cohort of patients and defined the MTD, pharmacokinetics, and safety in patients with relapsed or refractory hematologic malignancies.